Though baseline PD-L1 expression is widely used as a biomarker in clinical practice, it is valid only in limited cancers such as NSCLC, urothelial, and head and neck (H&N) squamous cell cancers, and also, patients with PD-L1 negative tumors can benefit from PD-(L)1 inhibitor therapy. Here, CD274 is linked to cancer.